|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/24/22 CollPlant Biotechnologies Ltd. 20-F 12/31/21 80:8.1M EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual Report HTML 1.54M
2: EX-8.1 Subsidiaries of the Company HTML 23K
5: EX-13.1 Annual or Quarterly Report to Security Holders HTML 23K
6: EX-13.2 Annual or Quarterly Report to Security Holders HTML 23K
3: EX-12.1 Statement re: the Computation of Ratios HTML 26K
4: EX-12.2 Statement re: the Computation of Ratios HTML 27K
7: EX-15.1 Consent of Kost Forer Gabbay & Kasierer, A Member HTML 22K
Firm of Ernst & Young Global, Independent
Registered Public Accounting Firm
8: EX-15.2 Consent of Kesselman & Kesselman, A Member Firm of HTML 23K
Pricewaterhousecoopers International Limited,
Independent Registered Public Accounting Firm.
14: R1 Document And Entity Information HTML 97K
15: R2 Consolidated Balance Sheets HTML 139K
16: R3 Consolidated Balance Sheets (Parentheticals) HTML 32K
17: R4 Consolidated Statements of Operation HTML 88K
18: R5 Consolidated Statements of Shareholders? Equity HTML 82K
19: R6 Consolidated Statements of Shareholders? Equity HTML 28K
(Parentheticals)
20: R7 Consolidated Statements of Cash Flows HTML 127K
21: R8 General HTML 28K
22: R9 Significant Accounting Policies HTML 90K
23: R10 Fair Value Measurements HTML 35K
24: R11 Property and Equipment HTML 32K
25: R12 Inventories HTML 28K
26: R13 Operating Leases HTML 43K
27: R14 Commitments HTML 29K
28: R15 Development , Exclusivity and Option Products HTML 38K
Agreements
29: R16 Share Capital HTML 121K
30: R17 Income Tax HTML 39K
31: R18 Supplementary Financial Statement Information HTML 54K
32: R19 Subsequent Events HTML 26K
33: R20 Accounting Policies, by Policy (Policies) HTML 313K
34: R21 Significant Accounting Policies (Tables) HTML 27K
35: R22 Fair Value Measurements (Tables) HTML 34K
36: R23 Property and Equipment (Tables) HTML 31K
37: R24 Inventories (Tables) HTML 28K
38: R25 Operating Leases (Tables) HTML 40K
39: R26 Share Capital (Tables) HTML 88K
40: R27 Income Tax (Tables) HTML 33K
41: R28 Supplementary Financial Statement Information HTML 58K
(Tables)
42: R29 Significant Accounting Policies (Details) HTML 38K
43: R30 Significant Accounting Policies (Details) - HTML 46K
Schedule of estimated useful lives property and
equipment
44: R31 Fair Value Measurements (Details) HTML 26K
45: R32 Fair Value Measurements (Details) - Schedule of HTML 34K
assumptions used for the models
46: R33 Fair Value Measurements (Details) - Schedule of HTML 30K
level 3 anti-dilution instrument
47: R34 Property and Equipment (Details) HTML 27K
48: R35 Property and Equipment (Details) - Schedule of HTML 46K
property and equipment
49: R36 Inventories (Details) HTML 25K
50: R37 Inventories (Details) - Schedule of inventories HTML 29K
51: R38 Operating Leases (Details) HTML 42K
52: R39 Operating Leases (Details) - Schedule of HTML 26K
supplemental cash flow information related to
leases
53: R40 Operating Leases (Details) - Schedule of HTML 40K
supplemental balance sheet information related to
leases
54: R41 Operating Leases (Details) - Schedule of HTML 41K
maturities of lease liabilities
55: R42 Commitments (Details) HTML 30K
56: R43 Development , Exclusivity and Option Products HTML 33K
Agreements (Details)
57: R44 Share Capital (Details) HTML 275K
58: R45 Share Capital (Details) - Schedule of shares HTML 45K
issued granted options
59: R46 Share Capital (Details) - Schedule of fair value HTML 42K
of options granted to employees on the date of
grant was computed using the Black-Scholes model
60: R47 Share Capital (Details) - Schedule of changes in HTML 54K
number of options granted
61: R48 Share Capital (Details) - Schedule of fair value HTML 36K
of options granted to non-employees
62: R49 Share Capital (Details) - Schedule of changes in HTML 49K
number of options granted
63: R50 Share Capital (Details) - Schedule of outstanding HTML 80K
and exercisable options
64: R51 Share Capital (Details) - Schedule of share-based HTML 32K
compensation
65: R52 Income Tax (Details) HTML 29K
66: R53 Income Tax (Details) - Schedule of deferred income HTML 34K
taxes
67: R54 Income Tax (Details) - Schedule of valuation HTML 28K
allowance
68: R55 Supplementary Financial Statement Information HTML 25K
(Details)
69: R56 Supplementary Financial Statement Information HTML 33K
(Details) - Schedule of balance sheet
70: R57 Supplementary Financial Statement Information HTML 38K
(Details) - Schedule of disaggregated revenues
text block
71: R58 Supplementary Financial Statement Information HTML 38K
(Details) - Schedule of revenues by geographical
area
72: R59 Supplementary Financial Statement Information HTML 38K
(Details) - Schedule of revenue by major customers
73: R60 Supplementary Financial Statement Information HTML 37K
(Details) - Schedule of changes in deferred
revenues relating to goods
74: R61 Supplementary Financial Statement Information HTML 39K
(Details) - Schedule of Financial income
(expenses) ,net
75: R62 Subsequent Events (Details) HTML 27K
78: XML IDEA XML File -- Filing Summary XML 147K
76: XML XBRL Instance -- f20f2021_collplantbio_htm XML 1.47M
77: EXCEL IDEA Workbook of Financial Reports XLSX 108K
9: EX-101.CAL XBRL Calculations -- clgn-20211231_cal XML 87K
10: EX-101.DEF XBRL Definitions -- clgn-20211231_def XML 718K
11: EX-101.LAB XBRL Labels -- clgn-20211231_lab XML 1.33M
12: EX-101.PRE XBRL Presentations -- clgn-20211231_pre XML 704K
13: EX-101.SCH XBRL Schema -- clgn-20211231 XSD 217K
79: JSON XBRL Instance as JSON Data -- MetaLinks 359± 479K
80: ZIP XBRL Zipped Folder -- 0001213900-22-014666-xbrl Zip 509K
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-229163 and 333-248479) pertaining to the Employees' Savings Plan of CollPlant Biotechnologies Ltd., and to the incorporation by reference in the Registration Statement (Form F-3 No. 333-228054 and 333-238731) of CollPlant Biotechnologies Ltd., and related prospectus of our report dated March 24, 2022, with respect to the consolidated financial statements of CollPlant Biotechnologies Ltd. included in this Annual Report (Form 20-F) for the year ended December 31, 2021.
/s/ Kost Forer Gabbay & Kaiserer
Kost Forer Gabbay & Kasierer
A Member of Ernst & Young Global
Tel Aviv, Israel
March 24, 2022
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/24/22 | 6-K | ||
| For Period end: | 12/31/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/04/24 CollPlant Biotechnologies Ltd. 20-F 12/31/23 74:6.9M EdgarAgents LLC/FA 3/29/23 CollPlant Biotechnologies Ltd. 20-F 12/31/22 73:6.8M EdgarAgents LLC/FA 12/30/22 CollPlant Biotechnologies Ltd. F-3 6:415K EdgarAgents LLC/FA 3/25/22 CollPlant Biotechnologies Ltd. S-8 3/25/22 4:81K EdgarAgents LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/26/21 CollPlant Biotechnologies Ltd. 20-F 12/31/20 83:7.9M EdgarAgents LLC/FA 2/17/21 CollPlant Biotechnologies Ltd. 6-K 2/17/21 3:242K EdgarAgents LLC/FA 4/07/20 CollPlant Biotechnologies Ltd. 6-K 4/07/20 5:1.6M EdgarAgents LLC/FA 4/01/20 CollPlant Biotechnologies Ltd. 20-F 12/31/19 78:6.9M EdgarAgents LLC/FA 4/01/19 CollPlant Biotechnologies Ltd. 20-F 12/31/18 96:8.5M EdgarAgents LLC/FA 3/20/18 CollPlant Biotechnologies Ltd. 20-F 12/31/17 95:8M EdgarAgents LLC/FA 1/23/18 CollPlant Biotechnologies Ltd. F-1/A 7:3.8M Toppan Merrill-FA 11/22/17 CollPlant Biotechnologies Ltd. F-1/A 12:4.6M Toppan Merrill-FA 10/21/16 CollPlant Biotechnologies Ltd. F-1 12:5.5M Toppan Merrill-FA 2/20/15 Bank of New York/ADR Division F-6 3:303K CollPlant Biotechnologies Ltd. Emmet Marvin & Mart… LLP |